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Abstract The specific V 2 agonist l-deamino [8-o-argininel- 
vasopressin (dDAVP), used for treatment of central diabetes 
insipidus, binds to vasopressin V2 receptors from human, bovine 
and rat kidney with an affinity that is similar to that of the natural 
hormone vasopressin. In contrast, the V1 receptors and the por- 
cine V2 receptor do not tolerate a n-arginine in position 8 of 
vasopressin. By site directed mutagenesis of the cloned bovine and 
porcine V 2 receptors we identified a residue (Asp-103) in the first 
extracellular loop of vasopressin receptors which is responsible 
for high affinity binding of dDAVP. 
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1. Introduction 
The neurohypophyseal nonapeptide arginine vasopressin 
(AVP) is the most important hormone regulating water reab- 
sorption in the mammalian kidney. The antidiuretic effect is 
mediated through the adenylate cyclase coupled V2 receptor 
located in the basolateral membrane of collecting ducts [1]. The 
hormonal induced increase of the cyclic AMP level results in 
the activation of cAMP dependent protein kinases. The final 
step of vasopressin action is the exocytic insertion of water 
channels into the apical membrane of collecting ducts [2,3] (for 
a recent review see [4]). 
The insufficiency of AVP caused by malfunction of AVP 
biosynthesis n the hypothalamo-neurohypophyseal system re- 
suits in the syndrome of central hypothalamic diabetes insip- 
idus (CDI) which is physiologically characterized by primary 
polyuria [5]. V2 receptor specific agonists and antagonists have 
been developed for treatment of disturbances in the vaso- 
pressin-regulated salt and water balances [6,7]. In 1968 the use 
of dDAVP (1-deamino [8-I>arginine]vasopressin) or desmo- 
pressin (Minirin) for therapy of CDI was reported for the first 
time [8] and has been successfully used for this indication ever 
since. This nonapeptide was obtained by two modifications of 
vasopressin [9]: deamination of the hemicystine in position 1 
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prolongs and enhances the antidiuretic effect and substitution 
of L-Arg to D-Arg in position 8 reduces pressor activity in rat 
bioassays [10]. 
At present, the molecular basis for the interaction of the V2 
receptor subtype with such specific ligands like dDAVP is un- 
known, although receptor cloning has shown that V~ and V2 
receptors belong to the G-protein coupled receptor family with 
seven transmembrane h lices [11-16]. Via , Vlb and V2 receptors 
have different ligand specificities and second messenger systems 
[17,18]. Recently, an extracellular agonist binding site in the 
renal V2 vasopressin receptor has been localized by a protein 
chemical approach [19]. Applying photoaffinity labeling with 
a radioactive agonist and sequencing of peptide fragments, 
amino acid residues in the second extracellular domain (first 
extracellular loop) of the bovine V2 receptor were identified as 
part of the hormone binding site. These results provide a basis 
for further studies of the relationship between structure and 
function of the V2 receptor by site directed in vitro mutagenesis 
of the cloned V2 receptor. The present work was performed to 
identify residues involved in hormone binding especially those 
which determine the high specificity for the V2 agonist dDAVP. 
2. Materials and methods 
2.1. Construction and screening of a cDNA library 
Messenger RNA was isolated from bovine kidneys by the guanidin- 
ium-thiocyanate method [20]. Poly(A)-RNA was purified by oligo(dT)- 
cellulose chromatography. The cDNA library was constructed by 
ligation of 1,3 8 kb sized cDNA, synthesized by Superscript reverse 
transcriptase (GibcoBRL), to 2gt lO-EcoRI-arms (Stratagene). A 32p_ 
labeled probe from the full-length porcine V2 receptor-DNA [14] was 
taken for screening of the Agt 10 cDNA library. Hybridization and 
washing was performed as previously described [14]. The inserts from 
recombinant phages were recloned into pGEM-7Zf(+) (Promega) and 
sequenced inboth directions with the Sequenase v rsion 2.0 kit (USB). 
The only full length clone was sequenced completely by application of 
the exonuclease III mung bean nuclease approach [21] and proper 
oligonucleotides. 
2.2. Mutagenesis 
Wild type cDNA of the bovine and porcine V2 receptor [14] was 
recloned in the mutagenesis plasmid pALTER-1 (PROMEGA). The 
mutants were constructed using a modified protocol from PROMEGA 
for oligonucleotide-mediated, site-directed mutagenesis. Mutagenesis 
was confirmed by DNA sequencing. 
2.3. Expression in COS cells 
The wild type bovine and porcine Vz receptor cDNA and their mu- 
tants were subcloned into the expression vector pCDM8 [22] (Invitro- 
gen) using BstXI-adapters. COS.M6 cells were transfected with the 
resulting plasmids using the DEAE-dextran method [14]. 72 h after 
transfection cells were removed from dishes by PBS/I mM EDTA 
treatment, collected by centrifugation at 1200 × g and resuspended in 
5 mM Tris-HC1 pH 7.4, 1 mM EDTA. Then they were homogenized 
with a Teflon-potter at 3000 rpm. Membranes were collected by centrif- 
ugation at 45,000 × g. The pellet was washed three times by centrifuga- 
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tion and resuspension i 15 mM HEPES pH 7.4, 1.5 mM MgCI 2. 
Membranes were frozen in aliquots at -80°C. The V2 receptor density 
for wild types and mutants was in all cases higher than 2.5 pmol per 
mg protein. 
2.4. Binding assay 
Saturation binding studies were performed at 30°C for 30 min in a 
total volume of 300 pl containing 26/tg membrane protein, 50 mM 
EPPS pH 8.3/5 mM MgCI 2 and various concentrations of [3H]AVP 
(411-736 GBq/mmol; NEN). Non-specific binding was determined in
the presence of 300-fold excess of non-radioactive AVP. Bound 
[3H]AVP was separated from free ligand by filtration through What- 
man GF/F filters. The same conditions were used for displacement 
experiments. In a total volume of 100 pl 10 nM [3H]AVP was displaced 
by several non-radioactive ligands in various concentrations. The bind- 
ing datas were analysed using the Ligand program [23] (Biosoft). Pep- 
tide ligands were obtained from Bachem, Heidelberg, the non-peptide 
V2 antagonist OPC-31260 was obtained from Otsuka America Pharma- 
ceutical, Inc., MD. 
3. Results and discussion 
The protein chemical identification of an extracellular ag- 
onist binding site in the renal V2 receptor has been recently 
performed on the V2 receptor protein isolated from bovine 
kidney membranes [19]. Using these results as a basis for fur- 
ther structure activity studies, site directed in vitro mutagenesis 
should be first performed on the V2 receptor cDNA from the 
same species. As no full length bovine V2 receptor cDNA has 
yet been cloned, a 2gtl0 cDNA library from bovine kidney 
medulla was constructed and screened with the 32p-labeled full- 
length porcine V2 receptor cDNA [14]. Analysis of 19 independ- 
ent recombinant bacteriophages showed different cDNA-sizes 
for each clone ranging between 500 bp and 1.6 kb. Only one 
clone represented a full-length cDNA. It was 1443 nucleotides 
long and had an open reading frame of 1110 nucleotides. 
The bovine V 2 receptor cDNA predicts a protein of 370 
amino acids with a calculated Mr of 40,236 in the absence of 
post-translational modifications (Fig. la). The amino acid se- 
quence identity with the human, rat and pig V2 receptors i 85%, 
82% and 88% respectively, with the human and rat Via recep- 
tors only 39%. 
The binding properties of the cloned bovine V2 receptor were 
examined after transient expression in COS M6 cells. Dose- 
dependent binding of [3H]AVP gave an apparent dissociation 
constant (Kd) of 0.5 nM. Competition binding experiments con- 
firmed that the cloned receptor has the typical pharmacological 
profile of the V2 subtype (Table 1). The most competent inhib- 
itor of [3H]AVP was the nonpeptide specific V2 antagonist 
OPC-31260 [7], (Ki = 0.2 nM), followed by AVP itself, (K i = 
1.3 nM), the specific V2 agonist dDAVP (K~ = 3.4 nM), 
[Lys8]vasopressin (LVP) (Ki = 4.4 nM) and oxytocin (Ki = 96 
nM). 
For further definition of the V2 receptor agonist binding site, 
residues for in vitro mutagenesis were selected based on the 
protein chemical labeling results on the one hand, and differ- 
ences in amino acid sequence and ligand selectivity of vaso- 
pressin receptors on the other hand. The sequence of the 18 
amino acids in the first extracellular loop is conserved within 
the cloned V2 receptors with only one substitution i  each V2 
receptor (Fig. lb). With respect o the affinity for the specific 
V2 agonist dDAVP, there exist differences between V2 receptors 
from different species which might be related to structural dif- 
ferences in their first extracellular loop: dDAVP binds to V2 
receptors from the human kidney [12,24], the rat kidney [13,25] 
and the bovine kidney (Table 1) with an affinity that is similiar 
to that for AVE In contrast, the affinity of the porcine V2 
receptor, which has [LysS]vasopressin as the natural igand, is 
for dDAVP more than 200-fold lower than for AVP [26]. A 
similar difference in affinity between dDAVP and AVP has 
been described for the V~a receptor from the human [27] and 
the rat liver [11] and for the Vlb from the rat pituitary receptor 
[28]. Whereas V2 receptors with high affinity for dDAVP have 
an aspartic acid residue in position 103, this residue is replaced 
in the porcine V2 receptor by tyrosine. A tyrosine residue is also 
present in the corresponding position of the cloned V~a and Vlb 
receptors (Fig. lb). 
These observations and the location of Asp-103 between the 
two photoaffinity-labeled r sidues Thr-102 and Arg-106 led us 
to the hypothesis that aspartic acid in position 103 of V2 recep- 
tors is involved in hormone binding, especially in high affinity 
binding for the V2 agonist dDAVP. To test this hypothesis, we 
exchanged by site directed in vitro mutagenesis Asp-103 
through tyrosine yielding the mutant bD103Y. Following this 
single mutation, the affinity for dDAVP decreased more than 
40-fold as compared to the wild type (Table 1, Fig. 2a and d), 
whereas the high affinity for AVP or for the specific V2 antag- 
onist OPC-31260 was retained. The reduction in affinity for 
dDAVP as compared to that for AVP could mainly be due to 
either the replacement of L-arginine in position 8 of AVP by the 
D-isomer in dDAVP or to the lack of an a-amino group in 
dDAVP. To test the influence of these substitutions separately, 
we determined the Ki values of the two analogues with one 
substitution: 1-deamino [Arg s] vasopressin (dAVP) and [D- 
ArgS]vasopressin (DAVP). Binding experiments showed (Table 
1, Fig. 2) that the bovine and porcine wild type V 2 receptors 
(Fig. 2a and b) and the mutant bD103Y (Fig. 2d) bind dAVP 
with the same or even slightly higher affinity than AVE In 
contrast, the replacement of L-arginine by its o-isomer in 
Table 1 
K, values (nM) of wildtype (wt) and mutated V2-receptors ~ 
Ligands bV2R (wt) bD103Y pV2R (wt) pYl02D pY102N bR106L 
AVP 1.31 1.87 2.46 7.13 15.95 1.38 
dDAVP 3.36 138.91 44.63 40.14 41.03 2.65 
dAVP 0.36 0.94 1.25 3.76 5.55 n.d. 
DAVP 0.92 40.81 72.67 6.82 10.47 n.d. 
OPC-31260 0.19 0.34 2.46 3.07 9.61 n.d. 
LVP 4.43 3.21 3.02 84.95 33.36 5.05 
OT 95.94 94.52 310.65 < 10,000 b 864.18 62.46 
"K~ values were calculated from displacement experiments a  shown in Fig. 2. 
b NO complete displacement was achieved. 
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Fig. 1. (a) Deduced amino acid sequence and schematic model of the bovine V2 receptor. (b) Comparison of the putative first extracellular loop from 
cloned V2 and V~ receptors. Transmembrane r gions were predicted by hydrophobicity analysis [30]. • marks an N-glycosylation site. Positions of 
site-directed in vitro mutagenesis (103 and 106) are indicated. Asterisks indicate the residues identified by photoaffinity labeling. BT, bovine; SS, 
porcine; HS, human; RN, rat. 
DAVP leads to a loss of affinity of the porcine V 2 receptor and 
the mutant bDI03Y. This reduction in affinity for DAVP is 
lower than that for dDAVP indicating an influence of the pro- 
tonated a-amino group on the conformation of the ligand. This 
effect has been previously reported for AVP [29]. Regression 
analysis of log Ki-values of the seven ligands (Table 1) deter- 
mined for the mutant bD103Y versus log K~-values for the 
porcine V2 receptor showed a correlation coefficient of 0.96, 
whereas for the two wild-type V 2 receptors a value of 0.65 was 
found. These results provide evidence that by single exchange 
of Asp-103 through tyrosine the differences in ligand specificity 
of the two V 2 receptors and especially the difference in affinity 
for ligands with D-arginine in position 8 like dDAVP and 
DAVP are determined. 
For verification of this observation we mutated the corre- 
sponding Tyr-residue (Tyr-102) in the porcine V2 receptor into 
the corresponding Asp-residue found in the human, bovine and 
rat V 2 receptor, which indeed turned the pharmacology of the 
mutant pY102D to a 10-fold higher affinity state for dDAVP 
and DAVE whereas the affinity for AVP slightly (3-fold) de- 
creased (Table 1, Fig. 2b and c). Regression analysis of six log 
K~ values determined for the mutant pY102D against he corre- 
sponding log K i values of wild type bovine V 2 receptor yielded 
a correlation coefficient of 0.94. The results of orthologues 
mutagenesis of both V2 receptors demonstrate hat the amino 
acid residue in position 103, respectively 102 located in the first 
extracellular loop of V 2 receptors determines the high affinity 
binding for the specific V 2 agonist dDAVP. The increase in the 
free energy of binding by introducing aspartic acid in this posi- 
tion could be due to the formation of a salt bridge between 
Asp-103 and D-arginine of the ligand. Alternatively, the weaker 
binding affinity for dDAVP and DAVP of receptors containing 
a tyrosine in this position could be explained by steric hin- 
drance due to the Tyr residue which may inhibit ion-ion binding 
of D-arginine in dDAVP but not of c-arginine in AVP with 
another acidic residue in the loop region. To discriminate 
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Fig. 2. Binding of AVP, dDAVP and analogues to wild type and mutant g 2 receptors. Membranes from COS.M6 cells expressing wild type (a) and 
the bD 103Y mutant (d) of the bovine V2 receptor were incubated with 10 nM [3H]AVP and increasing concentrations ofAVP (e), dDAVP (v), dAVP 
([]), and DAVP (©). Values of 100% corresponds tobinding of [3H]AVP found at the lowest concentration (10-~° M) of non-labeled ligand. The same 
procedure was performed with membranes from COS.M6 cells expressing wild type (b) and the pY102D mutant (c) of the porcine V2 receptor. Data 
were analysed by the LIGAND programm. The data shown are the means of duplicate values and are representative of two independent experiments. 
between these two possibilities we mutated Tyr-102 in the por- 
cine V2 receptor to an asparagine residue. This replacement 
again resulted in an increase of the affinity for the ligands with 
D-arginine in position 8 dDAVP and DAVP relative to that for 
AVE Regression analysis of the log K~ values (Table 1) deter- 
mined for the mutant pY102N against he Ki values for wild 
type bovine V2 receptor yielded a correlation coefficient of 0.96. 
These results demonstrate that replacement of Tyr-102 by 
either Asp or Asn in the porcine V2 receptor turns the pharma- 
cology to the higher affinity state for dDAVP. All mutated and 
wildtype receptors were able to stimulate adenylate cyclase in 
COS cells (results not shown). 
The results of the photoaffinity labeling experiments sug- 
gested that Arg-106 is close to the hormone binding site. We 
decided to substitute Arg-106 in the bovine V2 receptor by a 
non-charged leucine residue, whereas all V2 and V,a receptors 
exhibit in this position a positively charged amino acid. Binding 
experiments with the corresponding mutant bR106L exclude 
that a positively charged amino acid in position 106 is required 
for high affinity binding for any of the tested ligands to the V2 
receptor (Table 1). 
In conclusion, the high affinity of renal V2 receptors for the 
selective V2 agonist dDAVP can be abolished by substitution 
of Asp-103 against Tyr which is found in the corresponding 
position of V~ receptors. This mutation does not affect the 
affinity for the natural hormone AVP or a specific non-peptide 
V 2 antagonist. In the case of the porcine V2 receptor, which 
does not tolerate D-arginine in position 8 of vasopressin ana- 
logues, high affinity for dDAVP can be induced by replacement 
of the corresponding Tyr-102 in the porcine receptor against 
Asp or Asn. The observations suggest that steric requirements 
imposed by a D-arginine in position 8 of dDAVP and by the 
extracellular tyrosine in vasopressin receptors prevent their 
high affinity interaction. A single extracellular residue obvi- 
ously can determine the agonist specificity of receptor subtypes. 
The results hould provide the basis for a more detailed analysis 
of interaction between ligands and the vasopressin receptor by 
new mutagenesis experiments and for the development of spe- 
cific V2 agonists with further improved properties. 
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